Viral vectors, such as adeno-associated viruses (AAV) and lentiviral viruses (LVV), are recently at the forefront of biotherapeutic development for the support of cell and gene therapies. As with ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

With up to 2.4 million U.S. cases and over 250 million chronic cases globally, hepatitis B infection persists despite the availability of a vaccine. Vaccines work by immunizing the body against a ...

Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, today announced the significant expansion of its gene therapy platform.

(Nanowerk News) Bioengineers have found a way to program the size and shape of virus particles by combining viral protein building blocks and templates made from DNA. The resulting nanostructures ...

Though treatments are available, there is no cure or vaccine from HIV, which impacts about 38 million people worldwide. It's difficult to target the RNA genome of the HIV virus in part because it ...

High-quality HIV antigens for cutting-edge solutions. On February 18, 2025, Gilead Sciences (CA, US) announced a significant milestone: the US FDA accepted their New Drug Applications (NDAs) for ...

This is a preview. Log in through your library . Abstract Background. Naturally occurring variants of human papillomavirus (HPV) 58 have been defined as lineages and sublineages but little is known ...

A viral capsid is a structure that contains a virus’s genetic material; in the case of hepatitis B, the capsid is an icosahedral structure about 36 nanometers in diameter and composed of 240 identical ...

Proteins are responsible for many of the biological functions that make life possible. Michigan Tech researchers are gaining a better understanding of how they affect our day-to-day existence, vaccine ...